10-Q quarterly report · filed Oct 29, 2026

NovoCure Ltd (NVCR) Q3 2026 10-Q Quarterly Report

Short answer

NovoCure Ltd (NVCR) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $193M (up 15.7% year over year) with net income of −$10M.

Q3 2026 key financials · XBRL

Revenue
$193M
+15.7% YoY · +5.3% QoQ
Net income
−$10M
+72.0% YoY · +33.4% QoQ
Operating margin
-3.2%
Gross margin
77.0%
EPS (diluted)
−$0.09
+72.7% YoY · +30.8% QoQ

Source: XBRL data from the NovoCure Ltd (NVCR) Q3 2026 10-Q on SEC EDGAR. USD.

NovoCure Ltd Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $193.4M, up 16% YoY from $167.2M, driven by 19% global active-patient growth
  • Gross margin 77% vs 73% YoY, with Optune Lua revenue $8.2M and Optune Pax revenue $3.7M
  • Optune Pax fastest-growing product, $3.7M revenue vs $0.0M YoY; Optune Gio active patients 4,729
  • Cash, equivalents and short-term investments $463.5M, up $15.8M from December 31, 2025
  • Nine-month operating cash flow $17.3M vs $(31.0)M; tariff volatility and rising launch expenses remain headwinds

Risk Factors

  • No material changes to risk factors disclosed in the 2025 10-K
  • Carried-forward risks include regulatory, clinical, commercial, operational, and financial uncertainties
  • No new or materially updated risk identified in the quarter

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other NovoCure Ltd quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.